Levodopa is mainly used in the treatment of Parkinsonism, Parkinson’s plus syndrome, encephalitis-induced Parkinsonism, carbon monoxide or manganese poisoning-induced neuronal injury, and dopa-responsive dystonia. However, chronic administration of levodopa induces significant adverse effects which are primarily classified as the motor and non-motor complications. The levodopa-induced motor complications are fluctuations, dyskinesias, postural abnormalities, and freezing episodes. The non-motor complications are cognitive impairment, confusion, hallucinations, delusions, psychosis, agitation, nausea, dizziness, cardiac arrhythmias, postural-hypotension, headache, and somnolence. The other critical adverse effects include the greater risk of hip fractures, augmented homocysteine, decreased serum vitamin B₁₂, elevated methylmalonic acid, leading to sensory motor peripheral neuropathy. Furthermore, sudden withdrawal/dose reduction results in neuroleptic malignant / Parkinsonism hyperpyrexia syndrome. Due to the substantial adverse effects, the quality of patient’s life will be adversely affected. Interestingly, different levodopa formulation starts from the basic oral based formulations to otherdosage forms such as enteral / duodenal formulations for better efficacy and compliance. The current oral formulations include tablets, (Immediate-release, disintegrating, controlled-release, extended-release), extended-release capsules, suspension, and powder Inhalation. The other new formulation is the infusion.  However, these current dosage forms have receptor desensitization, decreased drug bioavailability, drug efficacy, and can generate free radicals that leads to neurotoxicity. Therefore, there is an imminent need to develop a novel dosage form for "Levodopa (gold-standard)”to treat various movement disorders.  Consequently, novel emulsion, topical, or other innovative formulations are immediately required to improve the CNS dopaminergic neurotransmission.